Membrane is a winner in the Innovation, Research & Development, and Environmental categories in the 2025 Pharmaceutical ...

Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...

Zambon Pharma has received approval from Chinese regulatory authorities and launched Fluimucil (N-acetylcysteine).

The FDA's new genAI-assisted scientific review technology, named Elsa, was officially adopted by the agency on 2 June.

The FDA has approved AstraZeneca and Daiichi Sankyo's Datroway (Datopotamab deruxtecan) for adults with NSCLC.

Navamedic has signed an agreement for the acquisition of Norwegian company dne pharma in a deal valued at Nkr225m ($22m).

The EC has approved argenx’s Vyvgart (efgartigimod alfa) 1000mg as a single agent for subcutaneous injection to treat CIDP.

An EMA committee has recommended approval of Alvotech’s AVT06, a biosimilar to Bayer’s blockbuster ophthalmology drug Eylea.

The FDA launched a new Priority Review program, as uncertainty persists for the existing programme for paediatric disorders.

Dedicated datasets highlight how social determinants of health can be used to improve overall standards of care.

Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.